Dr Sanjiv Agarwala predicts that the cancer biomarkers of the future may be “mobile biomarkers,†meaning measures of the tumor microenvironment or immune response that change with therapy and may be able to determine treatment efficacy.
Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library
Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.â€
Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library
Dr Sanjiv Agarwala describes best practices developed at St. Luke’s Cancer Center, where a committee has been formed in which clinicians and pathologists meet to reach consensus on reflex testing of molecular biomarkers, as well as the value of biomarker testing in enhancing patient care.
Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library
Dr Sanjiv Agarwala argues that much of the biomarker data in melanoma presented at ASCO 2018 are around the value of PD-L1 testing; however, even PD-L1–negative melanoma patients seem to respond to anti–PD-1 therapy, although some studies suggest PD-L1–negative patients may be better candidates for combination immunotherapy.
Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library
Dr David Spigel discusses challenges and solutions to incorporating cancer biomarkers into patient care, including finding pathology resources to do the testing, issues around reimbursement, and educating colleagues on the value and operational aspects of biomarker testing in delivering personalized therapy to patients with cancer.
Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library
Dr David Spigel talks about currently available and emerging biomarkers that predict the greatest sensitivity to immunotherapy, including his insight into PD-L1, MSI, and TMB.
Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library
Dr David Spigel reviews 3 of the most important, practice-changing topics at ASCO 2018: new therapies targeting RET in a number of tumor types, a prognostic biomarker assay to predict whether patients with breast cancer will need adjuvant hormonal therapy or chemotherapy, and the minimum level of PD-L1 positivity required [ Read More ]
Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library
Dr David Spigel discusses the 2 major themes highlighted at ASCO 2018: the use of cancer biomarkers to achieve precision therapy, and fine tuning treatment of patients with immunotherapy with respect to who to treat, how to treat, and how to predict clinical outcomes.
Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library